Women are more likely to have pulmonary arterial hypertension, but men tend to have worse outcomes and worse treatment responses.

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...

Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

Treatment response was also assessed ... Protein for Molecular Imaging of Fibrotic Remodeling in Pulmonary Arterial Hypertension, Journal of Nuclear Medicine (2025). DOI: 10.2967/jnumed.

The phase 3 HYPERION trial of Winrevair in adults with newly diagnosed pulmonary arterial hypertension functional class two ...

Merck plans to stop a late-stage study testing its drug to treat pulmonary arterial hypertension (PAH) ahead of time based on strong efficacy shown in previous studies, the drugmaker said on Thursday.

Combination therapy with oral or inhaled treprostinil may benefit patients with pulmonary arterial hypertension and cardiovascular comorbidities.

F-FAPI PET -- can detect the first signs of tissue remodeling in patients with pulmonary arterial hypertension (PAH), providing physicians with an early marker for disease progression. This approach ...

Shares in Keros Therapeutics fell sharply Wednesday morning after it said it halted trials of its treatment for ... which aims to treat pulmonary arterial hypertension. Write to Adriano Marchese ...